US Bancorp DE Trims Stake in Revvity, Inc. (NYSE:RVTY)

US Bancorp DE reduced its stake in Revvity, Inc. (NYSE:RVTY - Free Report) by 8.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 60,174 shares of the company's stock after selling 5,905 shares during the period. US Bancorp DE's holdings in Revvity were worth $7,687,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in RVTY. JFS Wealth Advisors LLC lifted its position in Revvity by 4,755.1% during the third quarter. JFS Wealth Advisors LLC now owns 2,379 shares of the company's stock worth $304,000 after purchasing an additional 2,330 shares during the period. First Trust Direct Indexing L.P. lifted its holdings in shares of Revvity by 36.3% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 2,983 shares of the company's stock worth $381,000 after acquiring an additional 794 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Revvity by 1.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 79,769 shares of the company's stock worth $10,190,000 after acquiring an additional 960 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Revvity in the third quarter valued at approximately $983,000. Finally, Custom Index Systems LLC raised its position in Revvity by 74.8% during the third quarter. Custom Index Systems LLC now owns 5,667 shares of the company's stock valued at $724,000 after purchasing an additional 2,425 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on RVTY. TD Cowen raised their target price on Revvity from $130.00 to $141.00 and gave the company a "buy" rating in a report on Tuesday, July 30th. Wells Fargo & Company began coverage on Revvity in a research note on Tuesday, August 27th. They set an "equal weight" rating and a $130.00 target price for the company. Leerink Partners raised their price target on shares of Revvity from $130.00 to $135.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. Bank of America upped their price objective on shares of Revvity from $118.00 to $127.00 and gave the stock a "neutral" rating in a research report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. raised their target price on shares of Revvity from $105.00 to $120.00 and gave the company a "neutral" rating in a research report on Tuesday, July 30th. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $128.79.

Revvity Trading Up 3.1 %

RVTY stock traded up $3.78 during trading on Monday, hitting $124.82. The company had a trading volume of 2,389,122 shares, compared to its average volume of 825,470. The company has a current ratio of 2.27, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40. Revvity, Inc. has a one year low of $82.17 and a one year high of $128.83. The business has a 50-day moving average of $121.39 and a 200-day moving average of $114.11. The stock has a market cap of $15.39 billion, a PE ratio of 92.17, a PEG ratio of 3.27 and a beta of 1.06.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.22%. The ex-dividend date of this dividend is Friday, January 17th. Revvity's dividend payout ratio (DPR) is 20.29%.

Insider Buying and Selling at Revvity

In other news, insider Tajinder S. Vohra sold 2,153 shares of the company's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $122.09, for a total value of $262,859.77. Following the completion of the sale, the insider now owns 23,960 shares in the company, valued at $2,925,276.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider Tajinder S. Vohra sold 2,154 shares of the business's stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the transaction, the insider now directly owns 19,652 shares in the company, valued at $2,392,237.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tajinder S. Vohra sold 2,153 shares of the company's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $122.09, for a total value of $262,859.77. Following the completion of the transaction, the insider now owns 23,960 shares in the company, valued at $2,925,276.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 7,807 shares of company stock valued at $937,576. Company insiders own 0.60% of the company's stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.